What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus?

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1628-1635

  Tayebjee, M H ^a   Lip, G Y H ^a   MacFadyen, Robert J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Atherosclerosis; Coronary artery disease; Extra cellular matrix; Matrix metalloproteinases; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; COLLAGENASE; GELATINASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CELL TYPE; ENZYME REGULATION; ENZYME RELEASE; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW;

ANIMALS; DIABETIC ANGIOPATHIES; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; RATS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 30044439402     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01675.x     Document Type: Review

References (53)

1. Lim H, MacFadyen RJ, Lip GYH. Diabetes, the renin-angiotensin aldosterone system and the heart. Arch Int Med 2004; 164: 1737-1748.
2. Thompson E. Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. Am J Anat 1988; 182: 270-282.
3. Spiro M, Crowley T. Increased rat myocardial type VI collagen in diabetes mellitus and hypertension. Diabetologia 1993; 36: 93-98.
4. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima fatty rats. Hypertension 1997; 29: 728-735.
5. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a Type II diabetic rat model. Circulation 2000; 101: 899-907.
6. Van Hoeven K, Factor S. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82: 848-855.
7. Goyal D, Choudhary A, Lip GYH, MacFadyen RJ. Diastolic heart failure: diagnosis recognition and management. Exp Op Pharmacother 2004; 5: 1745-1754.
8. Boyer J, Thanigaraj S, Schechtman K, Perez J. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93: 870-875.
9. Eren M, Gorgulu S, Uslu N, Celik S, Dadgeviren B, Tezel T. Relation between aortic stiffness and left ventricular diastolic dysfunction in patients with hypertension, diabetes or both. Heart 2004; 90: 37-43.
10. Turk Z, Misur I, Turk N, Benko B. Rat tissue collagen modified by advanced glycation: correlation with duration of diabetes and glycaemic control. Clin Chem Lab Med 1999; 37: 813-820.
11. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T et al. Immunohistochemical localisation of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Path 1993; 143: 1649-1656.
12. Rumble J, Cooper M, Soulis T, Cox A, Wu L, Youssef S et al. Vascular hypertrophy in experimental diabetes. J Clin Invest 1997; 99: 1016-1027.
13. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792.
14. Herrmann KL, McCulloch AD, Omens JH. Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 2003; 284: H1277-1284.
15. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.
16. McCawley L, Matrisian L. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opinion Cell Biol 2001; 13: 534-540.
17. Van den Steen P, Opdenakker G, Wormald M, Dwek R, Rudd P. Matrix remodeling enzymes, the protease cascade and glycosylation. Biochimica Biophysica Acta 2001; 1528: 61-73.
18. McGeehan G, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-561.
19. Brennan F, Browne K, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following antitumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997; 36: 643-650.
20. Dollery C, McEwan J, Henney A. Matrix metalloproteinases and cardiovascular disease. Circulation Res 1995; 77: 863.
21. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1b by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1b processing. J Immunol 1998; 161: 3340-3346.
22. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren Physiol Biochem 1994; 17: 316-325.
23. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int 1997; 52: 111-119.
24. McLennan S, Kelly D, Cox A, Cao Z, Lyons J, Yue D et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275.
25. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y et al. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995; 5: 1492-1497.
26. Lupia E, Elliot S, Lenz O, Zheng F, Hattori M, Striker G, Striker L. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 1999; 48: 1638-1644.
27. Aoyama T, Yamamoto S, Kanematsu A, Ogawa O, Tabata Y. Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice. Tissue Eng 2003; 9: 1289-1299.
28. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001; 21: 28-22.
29. Brown D, Hamdi H, Bahri S, Kenney M. Characterization of an endogenous metalloproteinase in human vitreous. Curr Eye Res 1994; 13: 639-647.
30. Salzmann J, Limb G, Khaw P, Gregor Z, Webster L, Chignell A et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 2000; 84: 1091-1096.
31. Jesmin S, Sakuma I, Hattori Y, Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodelling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 2003; 23: 2021-2026.
32. Portik-Dobos V, Anstadt M, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063-3068.
33. Jormsjo S, Ye S, Moritz J, Walter D, Dimmeler S, Zeiher A et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003.
34. Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H et al. Angiotensin II receptor blockade prevents microangiopathy and preserved diastolic function in the diabetic rat heart. Heart 2003; 89: 1236-1242.
35. Maxwell P, Timms P, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes. Diabet Med 2001; 18: 777-780.
36. Haffner S, Greenberg A, Weston W, Chen H, Williams K, Fred M. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
37. Marx N, Froehlich J, Siam L, Itner J, Wierse G, Schmidt A et al. Anti-diabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
38. Nakamura T, Matsuda T, Suzuki Y, Ureda Y, Koide H. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic haemodialysis patients with arteriosclerosis obliterans. ASAIO J 2003; 49: 430-434.
39. Tayebjee M, Lim H, MacFadyen R, Lip GYH. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and -2 in Type 2 diabetes mellitus: effect of one year's cardiovascular risk reduction therapy. Diabetes Care 2004; 27: 2049-2051.
40. Lim H, Tayebjee M, MacFadyen R, Lip GYH. Tissue inhibitor of matrix metalloproteinase-1 is a marker of left ventricular diastolic dysfunction in diabetic heart disease. J Am Coll Cardiol 2004; 43: 221A.
41. Grant M, Caballero S, Tarnuzzer R, Bass K, Ljubimov AV, Spoerri P et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 1998; 47: 1311-1317.
42. Kitsiou P, Tzinia A, Stetler-Stevenson W, Michael A, Fan W, Zhou B et al. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003; 284: F671-679.
43. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066-2073.
44. Singh R, Song R, Alavi N, Pegoraro A, Singh A, Leehey D. High glucose decrease matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-β1. Exp Nephrol 2001; 9: 249-257.
45. Fornoni A, Striker LJ, Zheng F, Striker GE. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002; 51: 499-505.
46. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618.
47. Rittie L, Berton A, Monboisse JC, Hornebeck W, Gillery P. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem Biophys Res Commun 1999; 264: 488-492.
48. Wall SJ, Sampson MJ, Levell N, Murphy G. Elevated matrix metalloproteinase-2 and -3 production from human diabetic dermal fibroblasts. Br J Dermatol 2003; 149: 13-16.
49. Mene P, Caenazzo C, Pugliese F, Cinotti GA, D'Angelo A, Garbisa S et al. Monocyte/mesangial cell interactions in high-glucose co-cultures. Nephrol Dial Transplant 2001; 16: 913-922.
50. Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 2001; 44: 433-436.
51. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-1298.
52. Hao F, Yu J. High glucose enhances expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 2003; 24: 534-538.
53. Death A, Fisher E, McGrath K, Yue D. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-269.